Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    International journal of radiation oncology, biology, physics. 2010 Jan 1. pii: S0360-3016(16)30428-X. doi: 10.1016/j.ijrobp.2016.06.102
    Radiation Therapy Utilization in Middle-Income Countries.
    Rosenblatt E1,  Fidarova E2,  Zubizarreta E3,  Barton MB4,  MacKillop W5,  Jones GW6,  Cordero LA7,  Yarney J8,  Lim GC9,  Gan J10,  Cernea V11,  Stojanovic-Rundic S12,  Strojan P13,  Kochbati L14,  Quarneti A15
    Author information
    1International Atomic Energy Agency, Vienna A-1400, Austria.
    2IAEA, Vienna, Austria.
    3International Atomic Energy Agency, Vienna, Austria.
    4University of New South Wales Australia, Sydney, Australia.
    5Kingston General Hospital, Ontario, ON, Canada.
    6Trillium Health Partners, Mississauga, ON, Canada.
    7Hospital Mexico, La Uruca, Costa Rica.
    8Korle Bu Teaching Hospital, Accra, Ghana.
    9National Cancer Institute, Putrajaya Malaysia, Putrajaya, Malaysia.
    10Jose R. Reyes Memorial Medical Centre, Manila, Philippines.
    11Oncology Institute Cluj-Napoca, Cluj Napoca, Romania.
    12Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
    13Institute of Oncology, radiation Oncology, Ljubljana, Slovenia.
    14Institut National de Cancer Salah Azaiz Ministère de la santé Publique, TUNIS, Tunisia.
    15Centro Hospitalario Pereira Rossell, Montevideo, Uruguay.
    Abstract

    OBJECTIVE: Primary aldosteronism (PA) is form of hypertension characterized by production of aldosterone by the adrenal that is excessive and relatively autonomous of the renin-angiotensin system. Once detected, unilateral PA can be usually cured by surgical removal of the affected adrenal, while bilateral PA can be specifically treated by medications, which antagonize aldosterone action. Clinical guidelines of Endocrine Societies in Europe and the US recommend screening for PA among most hypertensive patients. The incidence of PA among hypertensive patients varies from 5-30% between different studies. This may be due, at least in part, to variability in screening approaches and assay performance.

    DESIGN AND METHOD: There is an urgent need for a versatile PA screening approach that doesn't require withdrawal of potentially interfering medications and therefore allows the clear identification of PA patients without potentially complex and risky treatment amendments being necessary during the course of the diagnostic process. The Aldosterone-to-Angiotensin-II-Ratio (AA2-Ratio) is a novel LC-MS/MS based high-throughput test for PA that combines the plasma levels of aldosterone and physiologically active angiotensin II into a diagnostic ratio.

    RESULTS: The AA2-Ratio has the potential to be superior to the ARR in terms of its ability to discriminate between PA and other forms of hypertension, accuracy in measuring aldosterone, better reflecting the activity of the true direct circulating regulator of aldosterone (i.e. angiotensin II rather than renin), and being less affected by antihypertensive medications including ACE inhibitors. First data obtained in a proof-of-concept study investigating PA positive and negative patients proved the AA2-Ratio to be a powerful and cost-effective diagnostic tool for the diagnosis of PA among hypertensives.

    CONCLUSIONS: The availability of novel diagnostic approaches for the Renin-Angiotensin-Aldosterone-System (Equilibrium Analysis) might pave the way for Angiotensin peptides to be used in clinical routine testing by solving pre-analytic problems of analyte stability.


    Publikations ID: 27675913
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    21sextury.org fake hub hd sexy hub eroticax.org
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt